News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
688,043 Results
Type
Article (39153)
Company Profile (283)
Press Release (648607)
Section
Business (203904)
Career Advice (1996)
Deals (35372)
Drug Delivery (89)
Drug Development (80855)
Employer Resources (168)
FDA (16099)
Job Trends (14808)
News (344648)
Policy (32450)
Tag
Academia (2530)
Alliances (49188)
Alzheimer's disease (1262)
Approvals (16061)
Artificial intelligence (145)
Bankruptcy (352)
Best Places to Work (11582)
Biotechnology (200)
Breast cancer (190)
Cancer (1376)
Cardiovascular disease (110)
Career advice (1664)
Cell therapy (282)
Clinical research (64712)
Collaboration (485)
Compensation (263)
COVID-19 (2542)
C-suite (109)
Data (1394)
Diabetes (176)
Diagnostics (6170)
Earnings (84895)
Employer resources (146)
Events (110019)
Executive appointments (397)
FDA (16786)
Funding (431)
Gene therapy (195)
GLP-1 (599)
Government (4333)
Healthcare (18697)
Infectious disease (2635)
Inflammatory bowel disease (111)
Interviews (309)
IPO (16344)
Job creations (3625)
Job search strategy (1418)
Layoffs (418)
Legal (7862)
Lung cancer (198)
Manufacturing (207)
Medical device (13214)
Medtech (13219)
Mergers & acquisitions (19195)
Metabolic disorders (460)
Neuroscience (1584)
NextGen Class of 2024 (6500)
Non-profit (4467)
Northern California (1702)
Obesity (262)
Opinion (184)
Parkinson's disease (98)
Patents (120)
People (56464)
Phase I (20128)
Phase II (28501)
Phase III (21242)
Pipeline (514)
Postmarket research (2560)
Preclinical (8545)
Radiopharmaceuticals (236)
Rare diseases (264)
Real estate (5891)
Regulatory (21681)
Research institute (2310)
Resumes & cover letters (349)
Southern California (1471)
Startups (3562)
United States (15248)
Vaccines (564)
Weight loss (182)
Date
Today (108)
Last 7 days (561)
Last 30 days (2393)
Last 365 days (35302)
2024 (35145)
2023 (40076)
2022 (51173)
2021 (55711)
2020 (54086)
2019 (46541)
2018 (35020)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29266)
2010 (27328)
Location
Africa (714)
Arizona (196)
Asia (37280)
Australia (6088)
California (3835)
Canada (1458)
China (307)
Colorado (173)
Connecticut (178)
Europe (79837)
Florida (538)
Georgia (136)
Illinois (387)
Indiana (225)
Maryland (635)
Massachusetts (2975)
Michigan (175)
Minnesota (292)
New Jersey (1108)
New York (1091)
North Carolina (743)
Northern California (1702)
Ohio (146)
Pennsylvania (929)
South America (1093)
Southern California (1471)
Texas (555)
Utah (108)
Washington State (401)
688,043 Results for "medicinova inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
MediciNova Chief Business Officer David H. Crean, Ph.D. Assumes Communications Role Overseeing Investor Engagement and Public Relations
MediciNova, Inc. announces that its Chief Business Officer, David H. Crean, Ph.D., will assume management of the Company’s investor engagement, corporate communications, and public relations activities.
June 20, 2024
·
5 min read
Press Releases
MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders
November 20, 2024
·
8 min read
Biotech Beach
MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the Standard Market of the Tokyo Stock Exchange, announced that MediciNova conducted two poster presentations at the 92nd European Atherosclerosis Society 2024 Congress held online May 26-29, 2024.
May 28, 2024
·
9 min read
Biotech Beach
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer
MediciNova, Inc. announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 for the prevention of metastasis of eye cancer.
May 20, 2024
·
6 min read
Drug Development
MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024
MediciNova, Inc. announced that MediciNova’s collaborator, Gilbert Youssef, M.D. at Harvard Medical School, Attending Physician, Center for Neuro-Oncology at Dana-Farber Cancer Institute and Brigham and Women’s Hospital, presented new data and results of a Phase 1b/2a Clinical Trial of MN-166 in Glioblastoma at the American Society of Clinical Oncology Annual meeting 2024 held May 31- June 4th in Chicago, IL.
June 3, 2024
·
7 min read
Biotech Beach
MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)
MediciNova, Inc. announced that it has received an issue notification from the U.S. Patent and Trademark Office for a new patent which covers extended-release oral formulations of MN-166.
May 7, 2024
·
4 min read
Policy
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer
MediciNova, Inc. announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 for the prevention of metastasis in various cancers including pancreatic cancer, lung cancer, breast cancer, colorectal cancer, melanoma, and ovarian cancer.
June 5, 2024
·
5 min read
Biotech Beach
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome
MediciNova, Inc. announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 for the treatment of chlorine-induced acute respiratory distress syndrome.
May 14, 2024
·
5 min read
Biotech Beach
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan
MediciNova, Inc. today announced it has received a Notice of Allowance from the Japan Patent Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of macular injury associated with progressive multiple sclerosis.
March 26, 2024
·
5 min read
Press Releases
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver
November 15, 2024
·
6 min read
1 of 68,805
Next